Systemic Levels of Neuropeptide Y and Dipeptidyl Peptidase Activity in Patients with Ewing Sarcoma--associations with Tumor Phenotype and Survival

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2014 Nov 13

PMID 25387699

Citations 13

Authors

Jason U Tilan

Mark Krailo

Donald A Barkauskas

Susana Galli

Haifa Mtaweh

Jessica Long

Hongkun Wang

Kirsten Hawkins

Congyi Lu

Dima Jeha

Ewa Izycka-Swieszewska

Elizabeth R Lawlor

Jeffrey A Toretsky

Joanna B Kitlinska

Affiliations

Soon will be listed here.

Abstract

Background: Ewing sarcoma (ES) is driven by fusion of the Ewing sarcoma breakpoint region 1 gene (EWSR1) with an E26 transformation-specific (ETS) transcription factor (EWS-ETS), most often the Friend leukemia integration 1 transcription factor (FLI1). Neuropeptide Y (NPY) is an EWS-FLI1 transcriptional target; it is highly expressed in ES and exerts opposing effects, ranging from ES cell death to angiogenesis and cancer stem cell propagation. The functions of NPY are regulated by dipeptidyl peptidase IV (DPPIV), a hypoxia-inducible enzyme that cleaves the peptide and activates its growth-promoting actions. The objective of this study was to determine the clinically relevant functions of NPY by identifying the associations between patients' ES phenotype and their NPY concentrations and DPP activity.

Methods: NPY concentrations and DPP activity were measured in serum samples from 223 patients with localized ES and 9 patients with metastatic ES provided by the Children's Oncology Group.

Results: Serum NPY levels were elevated in ES patients compared with the levels in a healthy control group and an osteosarcoma patient population, and the elevated levels were independent of EWS-ETS translocation type. Significantly higher NPY concentrations were detected in patients with ES who had tumors of pelvic and bone origin. A similar trend was observed in patients with metastatic ES. There was no effect of NPY on survival in patients with localized ES. DPP activity in sera from patients with ES did not differ significantly from that in healthy controls and patients with osteosarcoma. However, high DPP levels were associated with improved survival.

Conclusions: Systemic NPY levels are elevated in patients with ES, and these high levels are associated with unfavorable disease features. DPPIV in serum samples from patients with ES is derived from nontumor sources, and its high activity is correlated with improved survival.

Citing Articles

Neuropeptide Y in cancer-biological functions and potential clinical implications.

Sigorski D, Sejda A, Abualsaud N, Krawczyk E, Izycka-Swieszewska E, Kitlinska J Cancer Metastasis Rev. 2025; 44(1):21.

PMID: 39760953 PMC: 11703900. DOI: 10.1007/s10555-024-10237-z.

Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.

Sanchez M, Rodriguez F, Covenas R Int J Mol Sci. 2023; 24(12).

PMID: 37373115 PMC: 10297964. DOI: 10.3390/ijms24129962.

Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship.

Ceranski A, Carreno-Gonzalez M, Ehlers A, Colombo M, Cidre-Aranaz F, Grunewald T Mol Cancer. 2023; 22(1):49.

PMID: 36915100 PMC: 10010019. DOI: 10.1186/s12943-023-01750-w.

Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread.

Sigorski D, Wesolowski W, Gruszecka A, Gulczynski J, Zielinski P, Misiukiewicz S J Cancer Res Clin Oncol. 2022; 149(9):5803-5822.

PMID: 36583743 PMC: 10356636. DOI: 10.1007/s00432-022-04540-x.

Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma.

Lu C, Mahajan A, Hong S, Galli S, Zhu S, Tilan J Nat Commun. 2022; 13(1):2323.

PMID: 35484119 PMC: 9051212. DOI: 10.1038/s41467-022-29898-x.

References

Mentlein R . Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul Pept. 1999; 85(1):9-24. DOI: 10.1016/s0167-0115(99)00089-0. View

Lee E, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P . Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest. 2003; 111(12):1853-62. PMC: 161419. DOI: 10.1172/JCI16929. View

Kogner P, Bjork O, Theodorsson E . Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol. 1993; 21(5):317-22. DOI: 10.1002/mpo.2950210502. View

Kogner P, Bjork O, Theodorsson E . Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval. Acta Paediatr. 1994; 83(4):423-7. DOI: 10.1111/j.1651-2227.1994.tb18134.x. View

deS Senanayake P, Denker J, Bravo E, Graham R . Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest. 1995; 96(5):2503-9. PMC: 185905. DOI: 10.1172/JCI118310. View

Dotsch J, Christiansen H, Hanze J, Lampert F, Rascher W . Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept. 1998; 75-76:185-90. DOI: 10.1016/s0167-0115(98)00067-6. View

Wirth M, Patz S, Wahle P . Transcellular induction of neuropeptide Y expression by NT4 and BDNF. Proc Natl Acad Sci U S A. 2005; 102(8):3064-9. PMC: 549439. DOI: 10.1073/pnas.0404712102. View

Kitlinska J, Abe K, Kuo L, Pons J, Yu M, Li L . Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res. 2005; 65(5):1719-28. DOI: 10.1158/0008-5472.CAN-04-2192. View

Bernstein M, Kovar H, Paulussen M, Randall R, Schuck A, Teot L . Ewing's sarcoma family of tumors: current management. Oncologist. 2006; 11(5):503-19. DOI: 10.1634/theoncologist.11-5-503. View

10.

Hancock J, Lessnick S . A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008; 7(2):250-6. DOI: 10.4161/cc.7.2.5229. View

11.

Granchi D, Baglio S, Amato I, Giunti A, Baldini N . Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells. Int J Cancer. 2008; 123(7):1526-35. DOI: 10.1002/ijc.23654. View

12.

Van Doorninck J, Ji L, Schaub B, Shimada H, Wing M, Krailo M . Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2010; 28(12):1989-94. PMC: 2860404. DOI: 10.1200/JCO.2009.24.5845. View

13.

Stulc T, Sedo A . Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract. 2010; 88(2):125-31. DOI: 10.1016/j.diabres.2010.02.017. View

14.

Ladenstein R, Potschger U, Cecile Le Deley M, Whelan J, Paulussen M, Oberlin O . Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28(20):3284-91. DOI: 10.1200/JCO.2009.22.9864. View

15.

Lu C, Everhart L, Tilan J, Kuo L, Sun C, Munivenkatappa R . Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene. 2010; 29(41):5630-42. PMC: 2955165. DOI: 10.1038/onc.2010.301. View

16.

Son M, Kim M, Yu K, Koo D, Cho Y . Involvement of neuropeptide Y and its Y1 and Y5 receptors in maintaining self-renewal and proliferation of human embryonic stem cells. J Cell Mol Med. 2009; 15(1):152-65. PMC: 3822502. DOI: 10.1111/j.1582-4934.2009.00956.x. View

17.

Lu C, Tilan J, Everhart L, Czarnecka M, Soldin S, Mendu D . Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem. 2011; 286(31):27494-505. PMC: 3149342. DOI: 10.1074/jbc.M111.224089. View

18.

Womer R, West D, Krailo M, Dickman P, Pawel B, Grier H . Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30(33):4148-54. PMC: 3494838. DOI: 10.1200/JCO.2011.41.5703. View

19.

Antonescu C . Round cell sarcomas beyond Ewing: emerging entities. Histopathology. 2013; 64(1):26-37. DOI: 10.1111/his.12281. View

20.

Tilan J, Lu C, Galli S, Izycka-Swieszewska E, Earnest J, Shabbir A . Hypoxia shifts activity of neuropeptide Y in Ewing sarcoma from growth-inhibitory to growth-promoting effects. Oncotarget. 2013; 4(12):2487-501. PMC: 3926843. DOI: 10.18632/oncotarget.1604. View